HN3 Stock Overview
Through its subsidiaries, operates as a biotechnology company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Restart Life Sciences Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.022 |
| 52 Week High | CA$0.032 |
| 52 Week Low | CA$0.0001 |
| Beta | 0.63 |
| 11 Month Change | 800.00% |
| 3 Month Change | -10.00% |
| 1 Year Change | 125.00% |
| 33 Year Change | -91.96% |
| 5 Year Change | -95.41% |
| Change since IPO | -99.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| HN3 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 27.8% | -0.7% | -0.02% |
| 1Y | 125.0% | -17.2% | 8.2% |
Return vs Industry: HN3 exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: HN3 exceeded the German Market which returned 8.2% over the past year.
Price Volatility
| HN3 volatility | |
|---|---|
| HN3 Average Weekly Movement | 4,799.0% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: HN3's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: HN3's weekly volatility has increased from 2436% to 4799% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | n/a | Steve Loutskou | www.restartlife.co |
Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing diagnostics and psilocybin-based therapeutics for the treatment of neuroinflammatory disorders, including autism spectrum disorder and fragile X syndrome. The company was formerly known as Nova Mentis Life Science Corp. and changed its name to Restart Life Sciences Corp. in November 2024.
Restart Life Sciences Corp. Fundamentals Summary
| HN3 fundamental statistics | |
|---|---|
| Market cap | €815.20k |
| Earnings (TTM) | -€431.86k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.9x
P/E RatioIs HN3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HN3 income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$628.58k |
| Earnings | -CA$628.58k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.021 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -5.7% |
How did HN3 perform over the long term?
See historical performance and comparison